A matter of motion or an emotional matter? Management of depression in Parkinson’s disease

References

• Parkinson J. An essay on the shaking palsy. 1817. J. Neuropsychiatry Clin. Neurosci. 14, 223–236 (2002).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Lim NG et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 67, 492–496 (1999).
   PubMed Web of Science ®Google Scholar
• Stefurak TM. Cortico-limbic dysfunction in depression: converging fingings in basal ganglia disease and primary affective disorders. In: Mental and Behavioral Dysfunction in Movement Disorders. Bedard A, Agid Y, Chouinard S, Fahn S, Korczyn A, Lespérance P (Eds). Humana Press, NJ, USA (2003).
   Google Scholar
• Lauterbach EC. The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr. Clin. North Am. 27, 801–825 (2004).
   PubMed Web of Science ®Google Scholar
• Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J. Neuropsychiatry Clin. Neurosci. 17, 214–220 (2005).
   PubMed Web of Science ®Google Scholar
• Azmitia EGP. The serotonergic system: a review of human and animal studies and a report on Macaca fascicularis. In: Myoclonus. Fahn S (Ed.). Raven Press, NY, USA (1985).
   Google Scholar
• Jellinger K. Overview of morphological changes in Parkinson's disease. IN Yahr MB (Ed.). Advances in Neurology: Parkinson's Disease. Raven Press, NY, USA (1986).
   Google Scholar
• Rihmer Z, Seregi K, Rihmer A. Parkinson's disease and depression. Neuropsychopharmacol. Hung. 6, 82–85 (2004).
   PubMedGoogle Scholar
• Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease. A community-based study. Arch. Neurol. 53, 175–179 (1996).
   PubMed Web of Science ®Google Scholar
• Allain H, Schuck S, Mauduit N. Depression in Parkinson's disease. Br. Med. J. 320, 1287–1288 (2000).
   PubMed Web of Science ®Google Scholar
• Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 13, 187–196 (2001).
   PubMed Web of Science ®Google Scholar
• Leentjens AF, Marinus J, Van Hilten JJ, Lousberg R, Verhey FR. The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson's disease: a discriminant analytic approach. J. Neuropsychiatry Clin. Neurosci. 15, 74–77 (2003).
   PubMed Web of Science ®Google Scholar
• Naarding P, Leentjens AF, van Kooten F, Verhey FR. Disease-specific properties of the Rating Scale for Depression in patients with stroke, Alzheimer's dementia, and Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 14, 329–334 (2002).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Recognition and treatment of depression in Parkinson's disease. J. Geriatr. Psychiatry Neurol. 16, 178–183 (2003).
   PubMed Web of Science ®Google Scholar
• Rojo A, Aguilar M, Garolera MT, Cubo E, Navas I, Quintana S. Depression in Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat. Disord. 10, 23–28 (2003).
   PubMed Web of Science ®Google Scholar
• Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 8, 193–197 (2002).
   PubMed Web of Science ®Google Scholar
• Meara J, Mitchelmore E, Hobson P. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. Age Ageing 28, 35–38 (1999).
   PubMed Web of Science ®Google Scholar
• Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The quality of life in Parkinson's disease. Mov. Disord. 15, 216–223 (2000).
   PubMed Web of Science ®Google Scholar
• Santamaria J, Tolosa E, Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 36, 1130–1133 (1986).
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Bolduc PL, Mayberg HS, Preziosi TJ, Robinson RG. Cognitive impairments and depression in Parkinson's disease: a follow up study. J. Neurol. Neurosurg. Psychiatry 53, 597–602 (1990).
   PubMed Web of Science ®Google Scholar
• Dooneief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch. Neurol. 49, 305–307 (1992).
   PubMedGoogle Scholar
• Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J. Neurol. Neurosurg. Psychiatry 49, 381–389 (1986).
   PubMed Web of Science ®Google Scholar
• Cummings JL. Depression and Parkinson's disease: a review. Am. J. Psychiatry 149, 443–454 (1992).
   PubMed Web of Science ®Google Scholar
• Schuurman AG, van den Akker M, Ensinck KT et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 58, 1501–1504 (2002).
   PubMed Web of Science ®Google Scholar
• Shiba M, Bower JH, Maraganore DM et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov. Disord. 15, 669–677 (2000).
   PubMed Web of Science ®Google Scholar
• Todes CJ, Lees AJ. The pre-morbid personality of patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 48, 97–100 (1985).
   PubMed Web of Science ®Google Scholar
• Robertson M. Depression in neurological disorders. In: Depression and Physical Illness. Robertson MK, Cornelius LE (Eds). John Wiley and Sons, Chichester, UK (1997).
   Google Scholar
• Ehmann TS, Beninger RJ, Gawel MJ, Riopelle RJ. Depressive symptoms in Parkinson's disease: a comparison with disabled control subjects. J. Geriatr. Psychiatry Neurol. 3, 3–9 (1990).
   PubMedGoogle Scholar
• Leentjens AF, Lousberg R, Verhey FR. Markers for depression in Parkinson's disease. Acta Psychiatr. Scand. 106, 196–201 (2002).
   PubMed Web of Science ®Google Scholar
• Kuzis G, Sabe L, Tiberti C, Leiguarda R, Starkstein SE. Cognitive functions in major depression and Parkinson disease. Arch. Neurol. 54, 982–986 (1997).
   PubMedGoogle Scholar
• Liu CY, Wang SJ, Fuh JL, Lin CH, Yang YY, Liu HC. The correlation of depression with functional activity in Parkinson's disease. J. Neurol. 244, 493–498 (1997).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J. Am. Geriatr. Soc. 52, 784–788 (2004).
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson's disease. J. Nerv. Ment. Dis. 178, 27–31 (1990b).
   PubMed Web of Science ®Google Scholar
• Zubenko GS. Biological correlates of clinical heterogeneity in primary dementia. Neuropsychopharmacology 6, 77–93 (1992).
   PubMed Web of Science ®Google Scholar
• Zweig RM, Ross CA, Hedreen JC et al. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann. Neurol. 24, 233–242 (1988).
   PubMed Web of Science ®Google Scholar
• Forstl H, Burns A, Levy R, Cairns N, Luthert P, Lantos P. Neurologic signs in Alzheimer's disease. Results of a prospective clinical and neuropathologic study. Arch. Neurol. 49, 1038–1042 (1992).
   PubMedGoogle Scholar
• Mayberg HS, Starkstein SE, Sadzot B et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann. Neurol. 28, 57–64 (1990).
   PubMed Web of Science ®Google Scholar
• Rogers D. Bradyphrenia in Parkinson's disease. In: Parkinson's Disease: Neurobehavioral Aspects. Huber SC (Ed.). Oxford University Press, NY, USA, (1992).
   Google Scholar
• Goodwin FK, Murphy DL, Brodie HK, Bunney WE Jr. L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients. Biol. Psychiatry 2, 341–366 (1970).
   PubMedGoogle Scholar
• Korf J, van Praag HM, Schut D, Nienhuis RJ, Lakke JP. Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy. Eur. Neurol. 12, 340–350 (1974).
   PubMed Web of Science ®Google Scholar
• Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety 11, 58–65 (2000).
   PubMed Web of Science ®Google Scholar
• Lemke MR, Fuchs G, Gemende I et al. Depression and Parkinson's disease. J. Neurol. 251(Suppl. 6), 24–27 (2004).
   PubMedGoogle Scholar
• Reichmann H, Brecht MH, Koster J, Kraus PH, Lemke MR. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease. CNS Drugs 17, 965–973 (2003).
   PubMed Web of Science ®Google Scholar
• Mayeux R, Stern Y, Cote L, Williams JB. Altered serotonin metabolism in depressed patients with parkinson's disease. Neurology 34, 642–646 (1984).
   PubMed Web of Science ®Google Scholar
• Malhi GS, Checkley SA. Olanzapine in the treatment of psychotic depression. Br. J. Psychiatry 174, 460 (1999).
   PubMedGoogle Scholar
• Malhi G, Berk M, Bourin M et al. Atypical mood stabilizers: a 'typical' role for atypical antipsychotics. Acta Psychiatr. Scand. 111, 29–38 (2005).
   PubMed Web of Science ®Google Scholar
• Cash R, Raisman R, Ploska A, Agid Y. High and low affinity [3H]imipramine binding sites in control and Parkinsonian brains. Eur. J. Pharmacol. 117, 71–80 (1985).
   PubMed Web of Science ®Google Scholar
• Backman J, Alling C, Alsen M, Regnell G, Traskman-Bendz L. Changes of cerebrospinal fluid monoamine metabolites during long-term antidepressant treatment. Eur. Neuropsychopharmacol. 10, 341–349 (2000).
   PubMed Web of Science ®Google Scholar
• Van Praag HM. Depression. Lancet 2, 1259–1264 (1982).
   PubMed Web of Science ®Google Scholar
• Hesse S, Barthel H, Schwarz J, Sabri O, Muller U. Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. Neurosci. Biobehav. Rev. 28, 547–563 (2004).
   PubMed Web of Science ®Google Scholar
• Meyer JH, Houle S, Sagrati S et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch. Gen. Psychiatry 61, 1271–1279 (2004).
   PubMed Web of Science ®Google Scholar
• Sargent PA, Kjaer KH, Bench CJ et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch. Gen. Psychiatry 57, 174–180 (2000).
   PubMed Web of Science ®Google Scholar
• Becker T, Becker G, Seufert J et al. Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography. J. Neurol. Neurosurg. Psychiatry 63, 590–596 (1997).
   PubMed Web of Science ®Google Scholar
• Mayeux R. Depression in the patient with Parkinson's disease. J. Clin. Psychiatry 51, 20–25 (1990).
   PubMedGoogle Scholar
• Mayberg HS. Frontal lobe dysfunction in secondary depression. J. Neuropsychiatry Clin. Neurosci. 6, 428–442 (1994).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Post mortem studies in Parkinson's disease – is it possible to detect brain areas for specific symptoms? J. Neural Transm. Suppl. 56, 1–29 (1999).
   Google Scholar
• Murai T, Muller U, Werheid K et al. In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 13, 222–228 (2001).
   PubMed Web of Science ®Google Scholar
• Zgaljardic DJ, Borod JC, Foldi NS, Mattis P. A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry. Cogn. Behav. Neurol. 16, 193–210 (2003).
   PubMedGoogle Scholar
• Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC. Risk factors for Parkinson's disease. Neurology 43, 1693–1697 (1993).
   PubMed Web of Science ®Google Scholar
• Taylor CA, Saint-Hilaire MH, Cupples LA et al. Environmental, medical, and family history risk factors for Parkinson's disease: a New England-based case control study. Am. J. Med. Genet. 88, 742–749 (1999).
   PubMed Web of Science ®Google Scholar
• Caspi A, Sugden K, Moffitt TE et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301, 386–389 (2003).
   PubMed Web of Science ®Google Scholar
• Mossner R, Henneberg A, Schmitt A et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol. Psychiatry 6, 350–352 (2001).
   PubMed Web of Science ®Google Scholar
• Menza MA, Palermo B, DiPaola R, Sage JI, Ricketts MH. Depression and anxiety in Parkinson's disease: possible effect of genetic variation in the serotonin transporter. J. Geriatr. Psychiatry Neurol. 12, 49–52 (1999).
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 55, 377–382 (1992).
   PubMed Web of Science ®Google Scholar
• Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry 4, 561–571 (1961).
   PubMed Web of Science ®Google Scholar
• Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson's disease? Psychol. Med. 31, 65–73 (2001).
   PubMed Web of Science ®Google Scholar
• Cheng EM, Siderowf A, Swarztrauber K, Eisa M, Lee M, Vickrey BG. Development of quality of care indicators for Parkinson's disease. Mov. Disord. 19, 136–150 (2004).
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg MA. New depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382–389 (1979).
   PubMed Web of Science ®Google Scholar
• Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br. J. Psychiatry 167, 99–103 (1995).
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23, 56–62 (1960).
   PubMed Web of Science ®Google Scholar
• Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int. J. Geriatr. Psychiatry 15, 644–649 (2000).
   PubMed Web of Science ®Google Scholar
• Leentjens AF, Verhey FR, Luijckx GJ, Troost J. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov. Disord. 15, 1221–1224 (2000).
   PubMed Web of Science ®Google Scholar
• Franz M, Lemke MR, Meyer T, Ulferts J, Puhl P, Snaith RP. German version of the Snaith-Hamilton Pleasure Scale (SHAPS-D). Anhedonia in schizophrenic and depressive patients. Fortschr. Neurol. Psychiatr. 66, 407–413 (1998).
   PubMed Web of Science ®Google Scholar
• Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov. Disord. 17, 445–454 (2002).
   PubMed Web of Science ®Google Scholar
• Yesavage JA. Geriatric Depression Scale. Psychopharmacol. Bull. 24, 709–711 (1988).
   PubMed Web of Science ®Google Scholar
• Beekman A. Diagnostic procedures in depression in Parkinson's disease: epidemiology and management. In: Mental Dysfunction in Parkinson's Disease. Wolters ESP, Berendse HW (Eds). Academic Pharmaceutical Productions, Utrecht, The Netherlands (1999).
   Google Scholar
• Marinus J, Leentjens AF, Visser M, Stiggelbout AM, van Hilten JJ. Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease. Clin. Neuropharmacol. 25, 318–324 (2002).
   PubMed Web of Science ®Google Scholar
• Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J. Comp. Neurol. 287(3), 373–392 (1989).
   PubMed Web of Science ®Google Scholar
• Dell'Agnello G, Ceravolo R, Nuti A et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin. Neuropharmacol. 24, 221–227 (2001).
   PubMed Web of Science ®Google Scholar
• Gony M, Lapeyre-Mestre M, Montastruc JL. Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin. Neuropharmacol. 26, 142–145 (2003).
   PubMed Web of Science ®Google Scholar
• Andersen J, Aabro E, Gulmann N et al. Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. Acta. Neurol. Scand. 62(4), 210–219 (1980).
   PubMed Web of Science ®Google Scholar
• Neufeld MY, Rabey JM, Orlov E, Korczyn AD. Electroencephalographic findings with low-dose clozapine treatment in psychotic Parkinsonian patients. Clin. Neuropharmacol. 19(1), 81–86. (1996).
   PubMed Web of Science ®Google Scholar
• Wermuth L, Sorensen PS, Timm B et al. Depression in idiopathic Parkinson's disease treated with citalopram. A placebo controlled trial. Nordic J. Psychiatry 52, 163–169 (1998).
   Web of Science ®Google Scholar
• McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol. Psychiatry 54(3), 363–375 (2003).
   PubMed Web of Science ®Google Scholar
• Malhi GS, Parker GB, Gladstone G, Wilhelm K, Mitchell PB. Recognizing the anxious face of depression. J. Nerv. Ment. Dis. 190, 366–373 (2002).
   PubMed Web of Science ®Google Scholar
• Oertel WH, Ellgring H. Parkinson's disease–medical education and psychosocial aspects. Patient Educ. Couns. 26, 71–79 (1995).
   PubMed Web of Science ®Google Scholar
• Fall PA, Granerus AK. Maintenance ECT in Parkinson's disease. J. Neural Transm. 106, 737–741 (1999).
   PubMed Web of Science ®Google Scholar
• Moellentine C, Rummans T, Ahlskog JE et al. Effectiveness of ECT in patients with parkinsonism. J. Neuropsychiatry Clin. Neurosci. 10, 187–193 (1998).
   PubMed Web of Science ®Google Scholar
• Dragasevic N, Potrebic A, Damjanovic A, Stefanova E, Kostic VS. Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson's disease: an open study. Mov. Disord. 17, 528–532 (2002).
   PubMed Web of Science ®Google Scholar
• Mally J, Stone TW. Improvement in Parkinsonian symptoms after repetitive transcranial magnetic stimulation. J. Neurol. Sci. 162, 179–184 (1999).
   PubMed Web of Science ®Google Scholar
• Manes F, Jorge R, Morcuende M, Yamada T, Paradiso S, Robinson RG. A controlled study of repetitive transcranial magnetic stimulation as a treatment of depression in the elderly. Int. Psychogeriatr. 13, 225–231 (2001).
   PubMed Web of Science ®Google Scholar
• Wassermann EM, Lisanby SH. Therapeutic application of repetitive transcranial magnetic stimulation: a review. Clin. Neurophysiol. 112, 1367–1377 (2001).
   PubMed Web of Science ®Google Scholar
• Hoppe C, Helmstaedter C, Scherrmann J, Elger CE. Self-reported mood changes following 6 months of vagus nerve stimulation in epilepsy patients. Epilepsy Behav. 2, 335–342 (2001).
   PubMed Web of Science ®Google Scholar
• Elger G, Hoppe C, Falkai P, Rush AJ, Elger CE. Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Res. 42, 203–210 (2000).
   PubMed Web of Science ®Google Scholar
• Jobe PC, Dailey JW, Wernicke JF. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit. Rev. Neurobiol. 13, 317–356 (1999).
   PubMed Web of Science ®Google Scholar